MediciNova, Inc. a
biopharmaceutical company traded on the NASDAQ Global Market MNOV and
the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today
announced the publication of positive Phase 2 clinical results in two asthma
studies in the Journal of Asthma. The publication is entitled, "Evaluation of
Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta(2)-Adrenergic
Receptor Agonist for the Treatment of Asthma via Intravenous Infusion" and is
available online.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in